Validation of ERX-208 in Ovarian Cancer
Seattle, WA – September 23, 2024: Dr. Surya Viswanadhapalli and Etira founder Dr Ratna Vadlamudi presented a poster titled “The therapeutic potential of ERX-208, a potent inducer of ER stress, in the treatment of ovarian cancer” at the 15th Biennial Ovarian Cancer Research Symposium. The data establishes that ER stress in ovarian cancer (OCa) is targetable and the clinical utility of ERX-208.
In the poster, ERX-208 exhibited nanomolar in vitro potency against 17 different OCa cell lines (which encompass the 5 unique subtypes of OCa) and patient derived organoids but had minimal activity against normal ovarian surface epithelial cells. These findings were complemented with robust preclinical data showing the activity of ERX-208 both against OCa patient derived xenografts and cancer cell derived xenografts in vivo and patient derived explants ex vivo. Mechanistically, ERX-208 causes endoplasmic reticulum stress in OCa cells in LIPA-dependent manner. The data support the advancement of ERX-208 towards clinical trials in ovarian cancer.
Like ERX-315, ERX-208 was designed to target specific pathways that are critical for cancer cell survival and proliferation. This targeted approach helps to spare healthy cells, potentially reducing side effects commonly associated with cancer therapies. A clinical trial titled “A Phase 1 Trial of ERX-315 in Participants with Advanced Solid Tumors” is approved in Australia and will begin enrollment in the weeks to come.
